Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05180045
Other study ID # IRB00307545
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 17, 2023
Est. completion date October 1, 2025

Study information

Verified date April 2024
Source Johns Hopkins University
Contact Yvonne Commodore-Mensah, PhD, MHS, RN
Phone 410-614-1519
Email ycommod1@jhu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LINKED-BP Program is a patient-centered, multi-level intervention linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo) that links with all Bluetooth-enabled validated blood pressure (BP) devices, support from community health workers (CHWs), and BP measurement training at community health centers serving high-risk adults to prevent stage 2 hypertension (BP ≥ 140/90 mm Hg). The LINKED-BP Program study will recruit a total of 600 adults (30 from each practice) with elevated BP (120-129/<80 mm Hg) or untreated stage 1 hypertension (130-139/80-89 mm Hg) across 20 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors (HBPM) and will be managed by the patients' primary care clinicians as usual; and (2) the LINKED-BP Program or "intervention arm," which will include training of patients on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. The intervention period for each study participant is 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date October 1, 2025
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age as of the date of data extraction - Self-identify as non-Hispanic white, non-Hispanic African-American or Hispanic - Have elevated BP (120-129/<80 mm Hg) or untreated stage 1 hypertension (130-139/80-89 mm Hg) (defined by AHA's 2017 hypertension clinical guidelines) - Receives primary medical care at one of the participating community health centers and primary care practices Exclusion Criteria: - Age <18 years - Prescribed antihypertensive medication - Diagnosis of end-stage renal disease (ESRD) - Condition which interferes with outcome measurement (e.g., dialysis) - Serious medical condition which either limits life expectancy or requires active management (e.g., cancer) - Patients with serious cognitive impairment or other conditions preventing their participation in the intervention - Upper arm circumference >50 cm (maximum limit of the extra-large BP cuff) - Those planning to leave the practice or move out of the geographic area in 18 months - Those who no longer consider the practice site the location where they receive primary care - Unwillingness to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
LINKED-BP Program
The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.

Locations

Country Name City State
United States Johns Hopkins Community Physicians Remington Baltimore Maryland
United States Johns Hopkins Community Physicians Bowie Bowie Maryland
United States Johns Hopkins Community Physicians Brandywine Brandywine Maryland
United States Choptank Fassett Magee Medical and Cambridge Dental Center Cambridge Maryland
United States Choptank Denton Health Center Denton Maryland
United States Choptank Easton Health Center Easton Maryland
United States Choptank Federalsburg Medical and Dental Center Federalsburg Maryland
United States Johns Hopkins Community Physicians Fulton Fulton Maryland
United States Choptank Goldsboro Goldsboro Maryland
United States Choptank Bay Hundred Saint Michaels Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in systolic blood pressure Change in systolic blood pressure in millimeters of mercury (mmHg) over a 12 month period. Baseline and 12 months
Secondary Change in diastolic blood pressure Change in diastolic blood pressure in millimeters of mercury (mmHg) over a 12 month period. Baseline and 12 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A